

# APHON Slated Candidate for Secretary

## Scarlett Czarnecki MSN RN CPHON® FAPHON



### Current Position

Director-Patient Care, Pediatric Hematology/Oncology Service Line and Child Life Department  
 Loma Linda University Children's Hospital  
 Loma Linda, CA

### APHON Membership

APHON member since 2001

### Local Chapter Membership

Southern California (SCAPHON) Chapter member since 2001

### Candidate Statement

The opportunity to serve on APHON's Board of Directors represents both a culmination of my service and an opportunity to contribute to our nursing community at the highest level. Through years of volunteer leadership—from Southern California chapter roles to national committee chair service—APHON has been foundational to my growth as a pediatric hematology/oncology nurse and to my contributions to the profession.

These experiences have also provided deep insight into the organization's strategic priorities and governance, while allowing me to support the development of emerging leaders. In 2025, I was inducted as a Fellow of APHON (FAPHON), affirming my commitment to the organization and our profession.

As a Director at Loma Linda University Children's Hospital, I oversee operations for the pediatric hematology/oncology service line. This role offers a system-level perspective on advancing nursing practice, strengthening multidisciplinary collaboration, supporting the workforce, and improving outcomes for patients and families.

Through APHON, I have found not only professional development, but also a community grounded in a shared purpose: to elevate pediatric hematology/oncology nursing, represent it with integrity, and serve patients and colleagues wholeheartedly. If elected, I will lean into that purpose while strengthening leadership development, expanding member engagement, and supporting initiatives that advance pediatric hematology/oncology nursing.

### Qualifications

#### Education

- MSN, 2021, Western Governors University, College of Health Professions, Master of Science in Nursing- Leadership and Management
- BSN, 1999, Grand Canyon University, Samaritan College of Nursing, Bachelor of Science in Nursing

#### Certifications

- Fellow of the Association of Pediatric/Hematology Oncology Nurses (FAPHON), 2025
- Certified Pediatric Hematology/Oncology Nurse (CPHON)
- APHON Chemotherapy/Biotherapy Provider
- APHON Chemotherapy/Biotherapy Instructor

## APHON Headquarters

- Leadership Roles
  - APHON Leadership Development Committee, Inaugural Chair, 2023-2024
  - APHON Nominating Committee, Chair, 2022-2023, Member, 2020-2023
  - APHON Local Chapter Committee, Chair, 2020-2022, Member, 2017-2019
  - APHON Counts, Assistant Editor, 2022-2023
  - APHON Counts, Section Editor of Local Chapter News, 2020-2022
  - APHON Conference Planning Committee, Chair, 2019, Member, 2016-2019
  - APHON Rebranding Committee, 2016
  - APHON Website Redesign Committee, 2016
- Contributions
  - APHON Town Hall Moderator, various years, 2016-2025

## APHON Local Chapter

- SCAPHON Chapter
  - Member, 2001
  - Director at Large, 2022-current
  - President, 2011-2017
  - SCAPHON President Elect, 2010
  - Past President, 2017
  - Past Conference Planning Chair, 2010
  - Conference Planning Chair, 2006-2009
  - Fundraising Chair, 2003-2005

## Awards

- APHON Dr. Patricia Greene Leadership Award, September 2022
- SCAPHON Kathy Ruccione Founders Award for Excellence in Pediatric Hematology/Oncology Nursing, 2015
- Jessie Rees Foundation Caregiver of the Year, 2014

## Publications

**Czarnecki, S.** (2022). Local Chapter Prophylaxis: Succession Planning. *APHON Counts*, 36(1), 15. Chicago, IL: Association of Pediatric Hematology/Oncology Nurses.

Newman, M. & **Czarnecki, S.** (2020). Self-Care and Resilience: Giving to Ourselves What We Give to Others. *APHON Counts*, 34(2), 15-16. Chicago, IL: Association of Pediatric Hematology/Oncology Nurses.

DuBois, S. G., Granger, M. M., Groshen, S., Tsao-Wei, D., Shamirian, A., **Czarnecki, S.**, Goodarzian, F., Berkovich, R., Shimada, H., Mosse, Y. P., Shusterman, S., Cohn, S. L., Goldsmith, K. C., Weiss, B. D., Yanik, G. A., Twist, C., Irwin, M., Park, J. O., Marachelian, A., & Matthay, K. K. (2020). Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium. *Journal of Clinical Oncology*, 38(15\_suppl), 10500. [https://doi.org/10.1200/JCO.2020.38.15\\_suppl.10500](https://doi.org/10.1200/JCO.2020.38.15_suppl.10500)

DuBois, S. G., Granger, M. M., Groshen, S., Tsao-Wei, D., Ji, L., Shamirian, A., **Czarnecki, S.**, Goodarzian, F., Berkovich, R., Shimada, H., Villablanca, J. G., Vo, K. T., Pinto, N., Mosse, Y. P., Maris, J. M., Shusterman, S., Cohn, S. L., Goldsmith, K. C., Weiss, B., ... Matthay, K. K. (2021). Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: A report from NANT Consortium. *Journal of Clinical Oncology*, 39(31), 3506–3514. <https://doi.org/10.1200/JCO.21.00703>

- Maurer, B. J., Kang, M. H., Villablanca, J. G., Janeba, J., Groshen, S., Matthay, K. K., Sondel, P. M., Maris, J. M., Jackson, H. A., Goodarzian, F., Shimada, H., **Czarnecki, S.**, Hasenauer, B., Reynolds, C. P., & Marachelian, A. (2013). Phase I trial of Fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. *Pediatric Blood & Cancer*. Advance online publication. <https://doi.org/10.1002/pbc.24652>
- Kang, M. H., Villablanca, J. G., Glade Bender, J. L., Matthay, K. K., Groshen, S., Sposto, R., **Czarnecki, S.**, Ames, M. M., Reynolds, C. P., Marachelian, A., & Maurer, B. J. (2014). Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: A case report from a New Approaches to Neuroblastoma (NANT) Phase I study. *BMC Research Notes*, 7(256). <https://doi.org/10.1186/1756-0500-7-256>
- Villablanca, J. G., Volchenboun, S. L., Cho, H., Kang, M. H., Cohn, S. L., Anderson, C. P., Marachelian, A., Groshen, S., Tsao-Wei, D., Matthay, K. K., Maris, J. M., Hasenauer, C. E., **Czarnecki, S.**, Lai, H., Goodarzian, F., Shimada, H., & Reynolds, C. P. (2016). A phase I New Approaches to Neuroblastoma Therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent/refractory high-risk neuroblastoma. *Pediatric Blood & Cancer*, 63(8), 1349–1356. <https://doi.org/10.1002/pbc.25994>
- Marachelian, A., Villablanca, J. G., Liu, C. W., Liu, B., Goodarzian, F., Lai, H. A., Shimada, H., Tran, H. C., Parra, J. A., Gallego, R., Bedrossian, N., Young, S., **Czarnecki, S.**, Kennedy, R., Weiss, B. D., Goldsmith, K., Granger, M., Matthay, K. K., Groshen, S., Asgharzadeh, S., Sposto, R., & Seeger, R. C. (2017). Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis. *Clinical Cancer Research*, 23(18), 5374–5383. <https://doi.org/10.1158/1078-0432.CCR-16-2647>
- DuBois, S. G., Marachelian, A., Fox, E., Kudgus, R. A., Reid, J. M., Groshen, S., Malvar, J., Bagatell, R., Wagner, L., Maris, J. M., Hawkins, R., Courtier, J., Lai, H., Goodarzian, F., Shimada, H., **Czarnecki, S.**, Tsao-Wei, D., Matthay, K. K., & Mosse, Y. P. (2016). Phase I study of the Aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) trial. *Journal of Clinical Oncology*, 34(12), 1368–1375. <https://doi.org/10.1200/JCO.2015.65.4828>
- Yanik, G. A., Villablanca, J. G., Maris, J. M., Weiss, B., Groshen, S., Marachelian, A., Park, J. R., Tsao-Wei, D., Hawkins, R., Shulkin, B. L., Jackson, H., Goodarzian, F., Shimada, H., Courtier, J., Hutchinson, R., Haas-Koga, D., Hasenauer, C. B., **Czarnecki, S.**, Katzenstein, H. M., & Matthay, K. K. (2015). (131)I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Phase II study. *Biology of Blood and Marrow Transplantation*, 21(4), 673–681. <https://doi.org/10.1016/j.bbmt.2015.01.004>
- DuBois, S. G., Groshen, S., Park, J. R., Haas-Kogan, D. A., Yang, X., Geier, E., Chen, E., Giacomini, K., Weiss, B., Cohn, S. L., Granger, M. M., Yanik, G. A., Hawkins, R., Courtier, J., Jackson, H., Goodarzian, F., Shimada, H., **Czarnecki, S.**, Tsao-Wei, D., Villablanca, J. G., Marachelian, A., & Matthay, K. K. (2015). Phase 1 study of vorinostat as a radiation sensitizer with 131-I-MIBG for patients with relapsed or refractory neuroblastoma. *Clinical Cancer Research*, 21(12), 2715–2721. <https://doi.org/10.1158/1078-0432.CCR-14-2764>

## Professional Presentations

**Czarnecki S**, Maurer B, Glade-Bender J, Groshen S, Villablanca JG, Reynolds CP, Marachelian A. Study of Carrier Use and Administration of LXS Powder in Patients with Recurrent/Refractory Neuroblastoma within the New Approaches to Neuroblastoma Therapy (NANT) Consortium Study: NANT 2004-04. Oral Presentation at 2012 Advances in Neuroblastoma Research Meeting; Toronto, Canada.

**Czarnecki S** and Marachelian A. Creativity in the Carrier: Study of Carrier Use and Successful Administration of LXS Fenretinide Powder. Poster Presentation for Association of Pediatric Hematology/Oncology Nurses National Conference 2012; Pittsburgh, Pennsylvania.

DuBois SG, Mosse YP, Fox E, Reid J, Groshen S, Tsao-Wei D, **Czarnecki S**, Bagatell R, Maris JM, Wagner L, Marachelian A, Matthay KK. Phase I Study of the Aurora A Kinase Inhibitor MLN8237 with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma: A Report from the New Approaches to Neuroblastoma Therapy (NANT) Consortium. Oral Presentation at the 2014 Advances in Neuroblastoma Research Meeting; Cologne, Germany.

Villablanca JG, Volchenbourn S, Cohn S, Anderson C, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Hasenauer B, **Czarnecki S**, Jackson H, Goodarzian F, Shimada H, Bailey HH, Kang M, Reynolds CP. A Phase I Study of Buthionine Sulfoximine (BSO) and Melphalan (L-PAM) with Autologous Stem Cell Support for Recurrent/Resistant High-Risk Neuroblastoma: A New Approaches to Neuroblastoma Therapy study. Oral Presentation at the 2014 Advances in Neuroblastoma Research Meeting; Cologne, Germany.

APHON Conferences 2017-2022. Presenter at the Local Chapter Strategy Sessions each Meeting.